微小残存病変（MRD）検査の世界市場規模、シェア、産業動向分析レポート：アプリケーション別、エンドユーザー別、技術別、地域別展望と予測、2022年～2028年

微小残存病変（MRD）検査の世界市場規模は、2028年までに27億米ドルに達し、予測期間中にCAGR14.2%の市場成長率で上昇すると予測されています。

これらの疾患は、血液細胞の適切な生成と動作に影響を及ぼします。これらの悪性腫瘍は、異常細胞の無制限の増殖によって健康な血液細胞の発達が妨げられ、健康な細胞の正常な機能が阻害されることで形成されます。MRDは測定可能残存率検査とも呼ばれ、その検査方法は、がん治療の効果や今後の治療方針を指示する必要性を判断するために使用されます。

MRD検査は、白血病、リンパ腫、骨髄腫の3つの血液悪性腫瘍で最も多く実施されていますが、他の疾患の診断にも利用されることが研究されています。また、検査結果は患者さんの治療法のカスタマイズに活用できるため、オーダーメイド医療の開発にも役立つと考えられています。

COVID-19の影響度分析

パンデミックの緊急性に伴い、治療法の変更のスピードがかなり遅くなっています。そのため、新しい治療法である微小残存病変の測定による病勢評価や再発評価のための最適な時点の設定が十分に行えなかっています。そのため、治療期間や治療時点の適切な記述ができず、治療の強化が困難になっていました。したがって、COVID-19のパンデミックは、微小残存病変（MRD）検査市場にマイナスの影響を及ぼしました。

市場成長要因

世界の血液悪性腫瘍の症例数増加

過去数十年以来、血液学的悪性腫瘍の罹患率は著しく上昇しています。この増加には、血液がんのサブタイプの有病率の上昇も含まれています。例えば、白血病は2018年にがんに関連する死亡原因として第11位となりました。Surveillance, Epidemiology, and End Results（SEER）Programによると、この疾患は2022年に新たに出現したすべてのがん症例の約3.2％も占めています。

さまざまながんの診断と治療におけるMRD検査法の使用の拡大

MRD検査法は、その開発以来、様々な血液がんの診断に不可欠なものとなっています。急性リンパ性白血病（ALL）では、MRD検査はルーチン検査の不可欠な部分となっています。また、いくつかの研究では、MRD検査は、最初のALL療法に極めて有用な適切な治療法を決定する最も適切な方法であることが示唆されています。これらの検査は、再発の危険性がある患者を特定するのにも役立ちます。このような要因は、微小残存病変（MRD）検査市場の大幅な拡大を支援します。

市場抑制要因

MRD検査の適用に関する複雑で厳しい規制

他の治療・診断手法と同様に、微小残存病変（MRD）検査の手法もまた、これらの検査の使用と適合性に関連する特定の問題の対象となります。この問題は、検査によって異なります。例えば、マルチパラメーターフローサイトメトリー検査は、複雑なデータの可視化を含み、これらの検査では細胞遺伝学的特徴を検出することはできません。したがって、MRD検査の欠点とともに、厳しい規制が微小残存病変（MRD）検査市場の拡大と成長を妨げています。

技術展望

技術に基づいて、微小残存病変（MRD）検査市場は、フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンス（NGS）、およびその他の技術に分類されます。2021年の微小残存病変（MRD）検査市場では、ポリメラーゼ連鎖反応（PCR）セグメントが最も高い収益シェアを獲得しました。このセグメントの成長は、微小残存病変（MRD）検査におけるPCR診断装置の高い実用性と簡便性に起因するものです。また、PCR診断装置キットは、より高い感度で情報へのアクセス性を高めることができます。

アプリケーションの展望

微小残存病変（MRD）検査市場は、アプリケーション別に、血液悪性腫瘍、白血病、リンパ腫、固形腫瘍、その他のアプリケーションに分けられます。血液学的悪性腫瘍セグメントは、2021年に微小残存病変（MRD）検査市場で最大の収益シェアを獲得しました。骨髄などの造血組織で形成が始まるがんは、血液学的悪性腫瘍と呼ばれています。リンパ腫、多発性骨髄腫、白血病などは、すべて血液悪性腫瘍の一種です。PCR診断を用いたMRD検査により、末梢血や骨髄で検出される希少ながん細胞も含めて同定することができます。

エンドユーザーの展望

微小残存病変（MRD）検査市場は、エンドユーザーに基づき、病院・専門クリニック、診断ラボ、学術・研究機関、その他に区分されます。学術・研究機関セグメントは、2021年の微小残存病変（MRD）検査市場で顕著な成長率を獲得しました。学術・研究機関では、MRD検査により、希少がんを対象としたより多くの研究を実施することができます。また、MRD検査の結果は、臨床試験の結果に焦点を当てた報告書のエンドポイントとして含めることができるため、臨床現場でも利用が増加します。

地域別の概況

地域別に見ると、微小残存病変（MRD）検査市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。北米セグメントは、2021年の微小残存病変（MRD）検査市場において最高の収益シェアを調達しました。北米のMRD検査は、迅速な技術的進歩、研究開発費の増加、アプリケーションの増加とともに発展する特許プールの結果として発展しています。

目次

第1章 市場の範囲と調査手法

• 市場の定義
• 目的
• 市場規模
• セグメンテーション
  • 微小残存病変（MRD）検査の世界市場、用途別
  • 微小残存病変（MRD）検査の世界市場、エンドユーザー別
  • 微小残存病変（MRD）検査の世界市場、技術別
  • 微小残存病変（MRD）検査の世界市場、地域別
• 調査手法

第2章 市場概要

• イントロダクション
  • 概要説明
    • 市場の構成とシナリオ
• 市場に影響を与える主な要因
  • 市場促進要因
  • 市場の抑制要因

第3章 微小残存病変（MRD）検査の世界市場：アプリケーション別

• 血液悪性腫瘍の世界市場：地域別
• 白血病の世界市場：地域別
• リンパ腫の世界市場：地域別
• 固形がんの世界市場：地域別
• 地域別世界のその他市場

第4章 微小残存病変（MRD）検査の世界市場：エンドユーザー別

• 病院・専門クリニックの世界市場：地域別
• 診断ラボの世界市場：地域別
• 学術・研究機関の世界市場：地域別
• 世界のその他の市場：地域別

第5章 微小残存病変（MRD）検査の世界市場：技術別

• 世界のポリメラーゼ連鎖反応（PCR）市場：地域別
• 世界の次世代シーケンス（NGS）市場：地域別
• フローサイトメトリーの世界市場：地域別
• 世界の地域別その他市場

第6章 微小残存病変（MRD）検査の世界市場。地域別市場

• 北米
  • 北米の微小残存病変（MRD）検査の国別市場
    • 米国
    • カナダ
    • メキシコ
    • その他北米地域
• 欧州
  • 欧州の微小残存病変（MRD）検査市場：国別
    • ドイツ
    • 英国
    • フランス
    • ロシア
    • スペイン
    • イタリア
    • その他欧州
• アジア太平洋地域
  • アジア太平洋地域の微小残存病変（MRD）検査市場：国別
    • 中国
    • 日本
    • インド
    • 韓国
    • シンガポール
    • マレーシア
    • その他アジア太平洋地域
• LAMEA
  • LAMEAの微小残存病変（MRD）検査市場：国別
    • ブラジル
    • アルゼンチン
    • UAE
    • サウジアラビア
    • 南アフリカ
    • ナイジェリア
    • その他のLAMEA

第7章 企業プロファイル

• Bio-Rad Laboratories, Inc.
• Guardant Health, Inc.
• Invitae Corporation（ArcherDX, Inc.）
• Bio-Techne Corporation
• F. Hoffmann-La Roche Ltd.
• ICON plc（MolecularMD Corporation）
• Natera Inc.
• Sysmex Corporation
• Laboratory Corporation of America Holdings
• Invivoscribe, Inc.

LIST OF TABLES

• TABLE 1 Global Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 2 Global Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 3 Global Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 4 Global Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 5 Global Hematological Malignancies Market by Region, 2018 - 2021, USD Million
• TABLE 6 Global Hematological Malignancies Market by Region, 2022 - 2028, USD Million
• TABLE 7 Global Leukemia Market by Region, 2018 - 2021, USD Million
• TABLE 8 Global Leukemia Market by Region, 2022 - 2028, USD Million
• TABLE 9 Global Lymphoma Market by Region, 2018 - 2021, USD Million
• TABLE 10 Global Lymphoma Market by Region, 2022 - 2028, USD Million
• TABLE 11 Global Solid Tumors Market by Region, 2018 - 2021, USD Million
• TABLE 12 Global Solid Tumors Market by Region, 2022 - 2028, USD Million
• TABLE 13 Global Others Market by Region, 2018 - 2021, USD Million
• TABLE 14 Global Others Market by Region, 2022 - 2028, USD Million
• TABLE 15 Global Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 16 Global Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 17 Global Hospitals & Specialty Clinics Market by Region, 2018 - 2021, USD Million
• TABLE 18 Global Hospitals & Specialty Clinics Market by Region, 2022 - 2028, USD Million
• TABLE 19 Global Diagnostic Laboratories Market by Region, 2018 - 2021, USD Million
• TABLE 20 Global Diagnostic Laboratories Market by Region, 2022 - 2028, USD Million
• TABLE 21 Global Academic & Research Institutes Market by Region, 2018 - 2021, USD Million
• TABLE 22 Global Academic & Research Institutes Market by Region, 2022 - 2028, USD Million
• TABLE 23 Global Others Market by Region, 2018 - 2021, USD Million
• TABLE 24 Global Others Market by Region, 2022 - 2028, USD Million
• TABLE 25 Global Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 26 Global Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 27 Global Polymerase Chain Reaction (PCR) Market by Region, 2018 - 2021, USD Million
• TABLE 28 Global Polymerase Chain Reaction (PCR) Market by Region, 2022 - 2028, USD Million
• TABLE 29 Global Next-Generation Sequencing (NGS) Market by Region, 2018 - 2021, USD Million
• TABLE 30 Global Next-Generation Sequencing (NGS) Market by Region, 2022 - 2028, USD Million
• TABLE 31 Global Flow Cytometry Market by Region, 2018 - 2021, USD Million
• TABLE 32 Global Flow Cytometry Market by Region, 2022 - 2028, USD Million
• TABLE 33 Global Others Market by Region, 2018 - 2021, USD Million
• TABLE 34 Global Others Market by Region, 2022 - 2028, USD Million
• TABLE 35 Global Minimal Residual Disease Testing Market by Region, 2018 - 2021, USD Million
• TABLE 36 Global Minimal Residual Disease Testing Market by Region, 2022 - 2028, USD Million
• TABLE 37 North America Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 38 North America Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 39 North America Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 40 North America Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 41 North America Hematological Malignancies Market by Country, 2018 - 2021, USD Million
• TABLE 42 North America Hematological Malignancies Market by Country, 2022 - 2028, USD Million
• TABLE 43 North America Leukemia Market by Country, 2018 - 2021, USD Million
• TABLE 44 North America Leukemia Market by Country, 2022 - 2028, USD Million
• TABLE 45 North America Lymphoma Market by Country, 2018 - 2021, USD Million
• TABLE 46 North America Lymphoma Market by Country, 2022 - 2028, USD Million
• TABLE 47 North America Solid Tumors Market by Country, 2018 - 2021, USD Million
• TABLE 48 North America Solid Tumors Market by Country, 2022 - 2028, USD Million
• TABLE 49 North America Others Market by Country, 2018 - 2021, USD Million
• TABLE 50 North America Others Market by Country, 2022 - 2028, USD Million
• TABLE 51 North America Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 52 North America Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 53 North America Hospitals & Specialty Clinics Market by Country, 2018 - 2021, USD Million
• TABLE 54 North America Hospitals & Specialty Clinics Market by Country, 2022 - 2028, USD Million
• TABLE 55 North America Diagnostic Laboratories Market by Country, 2018 - 2021, USD Million
• TABLE 56 North America Diagnostic Laboratories Market by Country, 2022 - 2028, USD Million
• TABLE 57 North America Academic & Research Institutes Market by Country, 2018 - 2021, USD Million
• TABLE 58 North America Academic & Research Institutes Market by Country, 2022 - 2028, USD Million
• TABLE 59 North America Others Market by Country, 2018 - 2021, USD Million
• TABLE 60 North America Others Market by Country, 2022 - 2028, USD Million
• TABLE 61 North America Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 62 North America Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 63 North America Polymerase Chain Reaction (PCR) Market by Country, 2018 - 2021, USD Million
• TABLE 64 North America Polymerase Chain Reaction (PCR) Market by Country, 2022 - 2028, USD Million
• TABLE 65 North America Next-Generation Sequencing (NGS) Market by Country, 2018 - 2021, USD Million
• TABLE 66 North America Next-Generation Sequencing (NGS) Market by Country, 2022 - 2028, USD Million
• TABLE 67 North America Flow Cytometry Market by Country, 2018 - 2021, USD Million
• TABLE 68 North America Flow Cytometry Market by Country, 2022 - 2028, USD Million
• TABLE 69 North America Others Market by Country, 2018 - 2021, USD Million
• TABLE 70 North America Others Market by Country, 2022 - 2028, USD Million
• TABLE 71 North America Minimal Residual Disease Testing Market by Country, 2018 - 2021, USD Million
• TABLE 72 North America Minimal Residual Disease Testing Market by Country, 2022 - 2028, USD Million
• TABLE 73 US Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 74 US Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 75 US Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 76 US Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 77 US Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 78 US Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 79 US Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 80 US Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 81 Canada Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 82 Canada Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 83 Canada Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 84 Canada Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 85 Canada Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 86 Canada Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 87 Canada Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 88 Canada Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 89 Mexico Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 90 Mexico Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 91 Mexico Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 92 Mexico Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 93 Mexico Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 94 Mexico Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 95 Mexico Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 96 Mexico Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 97 Rest of North America Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 98 Rest of North America Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 99 Rest of North America Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 100 Rest of North America Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 101 Rest of North America Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 102 Rest of North America Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 103 Rest of North America Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 104 Rest of North America Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 105 Europe Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 106 Europe Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 107 Europe Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 108 Europe Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 109 Europe Hematological Malignancies Market by Country, 2018 - 2021, USD Million
• TABLE 110 Europe Hematological Malignancies Market by Country, 2022 - 2028, USD Million
• TABLE 111 Europe Leukemia Market by Country, 2018 - 2021, USD Million
• TABLE 112 Europe Leukemia Market by Country, 2022 - 2028, USD Million
• TABLE 113 Europe Lymphoma Market by Country, 2018 - 2021, USD Million
• TABLE 114 Europe Lymphoma Market by Country, 2022 - 2028, USD Million
• TABLE 115 Europe Solid Tumors Market by Country, 2018 - 2021, USD Million
• TABLE 116 Europe Solid Tumors Market by Country, 2022 - 2028, USD Million
• TABLE 117 Europe Others Market by Country, 2018 - 2021, USD Million
• TABLE 118 Europe Others Market by Country, 2022 - 2028, USD Million
• TABLE 119 Europe Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 120 Europe Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 121 Europe Hospitals & Specialty Clinics Market by Country, 2018 - 2021, USD Million
• TABLE 122 Europe Hospitals & Specialty Clinics Market by Country, 2022 - 2028, USD Million
• TABLE 123 Europe Diagnostic Laboratories Market by Country, 2018 - 2021, USD Million
• TABLE 124 Europe Diagnostic Laboratories Market by Country, 2022 - 2028, USD Million
• TABLE 125 Europe Academic & Research Institutes Market by Country, 2018 - 2021, USD Million
• TABLE 126 Europe Academic & Research Institutes Market by Country, 2022 - 2028, USD Million
• TABLE 127 Europe Others Market by Country, 2018 - 2021, USD Million
• TABLE 128 Europe Others Market by Country, 2022 - 2028, USD Million
• TABLE 129 Europe Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 130 Europe Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 131 Europe Polymerase Chain Reaction (PCR) Market by Country, 2018 - 2021, USD Million
• TABLE 132 Europe Polymerase Chain Reaction (PCR) Market by Country, 2022 - 2028, USD Million
• TABLE 133 Europe Next-Generation Sequencing (NGS) Market by Country, 2018 - 2021, USD Million
• TABLE 134 Europe Next-Generation Sequencing (NGS) Market by Country, 2022 - 2028, USD Million
• TABLE 135 Europe Flow Cytometry Market by Country, 2018 - 2021, USD Million
• TABLE 136 Europe Flow Cytometry Market by Country, 2022 - 2028, USD Million
• TABLE 137 Europe Others Market by Country, 2018 - 2021, USD Million
• TABLE 138 Europe Others Market by Country, 2022 - 2028, USD Million
• TABLE 139 Europe Minimal Residual Disease Testing Market by Country, 2018 - 2021, USD Million
• TABLE 140 Europe Minimal Residual Disease Testing Market by Country, 2022 - 2028, USD Million
• TABLE 141 Germany Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 142 Germany Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 143 Germany Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 144 Germany Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 145 Germany Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 146 Germany Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 147 Germany Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 148 Germany Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 149 UK Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 150 UK Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 151 UK Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 152 UK Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 153 UK Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 154 UK Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 155 UK Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 156 UK Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 157 France Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 158 France Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 159 France Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 160 France Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 161 France Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 162 France Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 163 France Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 164 France Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 165 Russia Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 166 Russia Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 167 Russia Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 168 Russia Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 169 Russia Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 170 Russia Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 171 Russia Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 172 Russia Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 173 Spain Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 174 Spain Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 175 Spain Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 176 Spain Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 177 Spain Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 178 Spain Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 179 Spain Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 180 Spain Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 181 Italy Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 182 Italy Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 183 Italy Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 184 Italy Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 185 Italy Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 186 Italy Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 187 Italy Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 188 Italy Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 189 Rest of Europe Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 190 Rest of Europe Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 191 Rest of Europe Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 192 Rest of Europe Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 193 Rest of Europe Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 194 Rest of Europe Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 195 Rest of Europe Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 196 Rest of Europe Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 197 Asia Pacific Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 198 Asia Pacific Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 199 Asia Pacific Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 200 Asia Pacific Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 201 Asia Pacific Hematological Malignancies Market by Country, 2018 - 2021, USD Million
• TABLE 202 Asia Pacific Hematological Malignancies Market by Country, 2022 - 2028, USD Million
• TABLE 203 Asia Pacific Leukemia Market by Country, 2018 - 2021, USD Million
• TABLE 204 Asia Pacific Leukemia Market by Country, 2022 - 2028, USD Million
• TABLE 205 Asia Pacific Lymphoma Market by Country, 2018 - 2021, USD Million
• TABLE 206 Asia Pacific Lymphoma Market by Country, 2022 - 2028, USD Million
• TABLE 207 Asia Pacific Solid Tumors Market by Country, 2018 - 2021, USD Million
• TABLE 208 Asia Pacific Solid Tumors Market by Country, 2022 - 2028, USD Million
• TABLE 209 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
• TABLE 210 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
• TABLE 211 Asia Pacific Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 212 Asia Pacific Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 213 Asia Pacific Hospitals & Specialty Clinics Market by Country, 2018 - 2021, USD Million
• TABLE 214 Asia Pacific Hospitals & Specialty Clinics Market by Country, 2022 - 2028, USD Million
• TABLE 215 Asia Pacific Diagnostic Laboratories Market by Country, 2018 - 2021, USD Million
• TABLE 216 Asia Pacific Diagnostic Laboratories Market by Country, 2022 - 2028, USD Million
• TABLE 217 Asia Pacific Academic & Research Institutes Market by Country, 2018 - 2021, USD Million
• TABLE 218 Asia Pacific Academic & Research Institutes Market by Country, 2022 - 2028, USD Million
• TABLE 219 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
• TABLE 220 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
• TABLE 221 Asia Pacific Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 222 Asia Pacific Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 223 Asia Pacific Polymerase Chain Reaction (PCR) Market by Country, 2018 - 2021, USD Million
• TABLE 224 Asia Pacific Polymerase Chain Reaction (PCR) Market by Country, 2022 - 2028, USD Million
• TABLE 225 Asia Pacific Next-Generation Sequencing (NGS) Market by Country, 2018 - 2021, USD Million
• TABLE 226 Asia Pacific Next-Generation Sequencing (NGS) Market by Country, 2022 - 2028, USD Million
• TABLE 227 Asia Pacific Flow Cytometry Market by Country, 2018 - 2021, USD Million
• TABLE 228 Asia Pacific Flow Cytometry Market by Country, 2022 - 2028, USD Million
• TABLE 229 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
• TABLE 230 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
• TABLE 231 Asia Pacific Minimal Residual Disease Testing Market by Country, 2018 - 2021, USD Million
• TABLE 232 Asia Pacific Minimal Residual Disease Testing Market by Country, 2022 - 2028, USD Million
• TABLE 233 China Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 234 China Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 235 China Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 236 China Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 237 China Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 238 China Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 239 China Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 240 China Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million

• TABLE 241 Japan Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 242 Japan Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 243 Japan Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 244 Japan Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 245 Japan Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 246 Japan Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 247 Japan Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 248 Japan Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 249 India Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 250 India Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 251 India Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 252 India Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 253 India Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 254 India Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 255 India Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 256 India Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 257 South Korea Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 258 South Korea Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 259 South Korea Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 260 South Korea Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 261 South Korea Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 262 South Korea Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 263 South Korea Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 264 South Korea Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 265 Singapore Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 266 Singapore Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 267 Singapore Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 268 Singapore Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 269 Singapore Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 270 Singapore Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 271 Singapore Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 272 Singapore Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 273 Malaysia Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 274 Malaysia Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 275 Malaysia Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 276 Malaysia Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 277 Malaysia Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 278 Malaysia Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 279 Malaysia Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 280 Malaysia Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 281 Rest of Asia Pacific Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 282 Rest of Asia Pacific Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 283 Rest of Asia Pacific Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 284 Rest of Asia Pacific Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 285 Rest of Asia Pacific Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 286 Rest of Asia Pacific Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 287 Rest of Asia Pacific Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 288 Rest of Asia Pacific Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 289 LAMEA Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 290 LAMEA Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 291 LAMEA Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 292 LAMEA Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 293 LAMEA Hematological Malignancies Market by Country, 2018 - 2021, USD Million
• TABLE 294 LAMEA Hematological Malignancies Market by Country, 2022 - 2028, USD Million
• TABLE 295 LAMEA Leukemia Market by Country, 2018 - 2021, USD Million
• TABLE 296 LAMEA Leukemia Market by Country, 2022 - 2028, USD Million
• TABLE 297 LAMEA Lymphoma Market by Country, 2018 - 2021, USD Million
• TABLE 298 LAMEA Lymphoma Market by Country, 2022 - 2028, USD Million
• TABLE 299 LAMEA Solid Tumors Market by Country, 2018 - 2021, USD Million
• TABLE 300 LAMEA Solid Tumors Market by Country, 2022 - 2028, USD Million
• TABLE 301 LAMEA Others Market by Country, 2018 - 2021, USD Million
• TABLE 302 LAMEA Others Market by Country, 2022 - 2028, USD Million
• TABLE 303 LAMEA Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 304 LAMEA Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 305 LAMEA Hospitals & Specialty Clinics Market by Country, 2018 - 2021, USD Million
• TABLE 306 LAMEA Hospitals & Specialty Clinics Market by Country, 2022 - 2028, USD Million
• TABLE 307 LAMEA Diagnostic Laboratories Market by Country, 2018 - 2021, USD Million
• TABLE 308 LAMEA Diagnostic Laboratories Market by Country, 2022 - 2028, USD Million
• TABLE 309 LAMEA Academic & Research Institutes Market by Country, 2018 - 2021, USD Million
• TABLE 310 LAMEA Academic & Research Institutes Market by Country, 2022 - 2028, USD Million
• TABLE 311 LAMEA Others Market by Country, 2018 - 2021, USD Million
• TABLE 312 LAMEA Others Market by Country, 2022 - 2028, USD Million
• TABLE 313 LAMEA Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 314 LAMEA Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 315 LAMEA Polymerase Chain Reaction (PCR) Market by Country, 2018 - 2021, USD Million
• TABLE 316 LAMEA Polymerase Chain Reaction (PCR) Market by Country, 2022 - 2028, USD Million
• TABLE 317 LAMEA Next-Generation Sequencing (NGS) Market by Country, 2018 - 2021, USD Million
• TABLE 318 LAMEA Next-Generation Sequencing (NGS) Market by Country, 2022 - 2028, USD Million
• TABLE 319 LAMEA Flow Cytometry Market by Country, 2018 - 2021, USD Million
• TABLE 320 LAMEA Flow Cytometry Market by Country, 2022 - 2028, USD Million
• TABLE 321 LAMEA Others Market by Country, 2018 - 2021, USD Million
• TABLE 322 LAMEA Others Market by Country, 2022 - 2028, USD Million
• TABLE 323 LAMEA Minimal Residual Disease Testing Market by Country, 2018 - 2021, USD Million
• TABLE 324 LAMEA Minimal Residual Disease Testing Market by Country, 2022 - 2028, USD Million
• TABLE 325 Brazil Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 326 Brazil Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 327 Brazil Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 328 Brazil Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 329 Brazil Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 330 Brazil Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 331 Brazil Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 332 Brazil Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 333 Argentina Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 334 Argentina Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 335 Argentina Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 336 Argentina Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 337 Argentina Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 338 Argentina Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 339 Argentina Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 340 Argentina Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 341 UAE Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 342 UAE Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 343 UAE Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 344 UAE Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 345 UAE Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 346 UAE Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 347 UAE Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 348 UAE Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 349 Saudi Arabia Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 350 Saudi Arabia Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 351 Saudi Arabia Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 352 Saudi Arabia Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 353 Saudi Arabia Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 354 Saudi Arabia Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 355 Saudi Arabia Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 356 Saudi Arabia Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 357 South Africa Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 358 South Africa Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 359 South Africa Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 360 South Africa Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 361 South Africa Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 362 South Africa Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 363 South Africa Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 364 South Africa Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 365 Nigeria Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 366 Nigeria Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 367 Nigeria Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 368 Nigeria Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 369 Nigeria Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 370 Nigeria Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 371 Nigeria Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 372 Nigeria Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 373 Rest of LAMEA Minimal Residual Disease Testing Market, 2018 - 2021, USD Million
• TABLE 374 Rest of LAMEA Minimal Residual Disease Testing Market, 2022 - 2028, USD Million
• TABLE 375 Rest of LAMEA Minimal Residual Disease Testing Market by Application, 2018 - 2021, USD Million
• TABLE 376 Rest of LAMEA Minimal Residual Disease Testing Market by Application, 2022 - 2028, USD Million
• TABLE 377 Rest of LAMEA Minimal Residual Disease Testing Market by End User, 2018 - 2021, USD Million
• TABLE 378 Rest of LAMEA Minimal Residual Disease Testing Market by End User, 2022 - 2028, USD Million
• TABLE 379 Rest of LAMEA Minimal Residual Disease Testing Market by Technology, 2018 - 2021, USD Million
• TABLE 380 Rest of LAMEA Minimal Residual Disease Testing Market by Technology, 2022 - 2028, USD Million
• TABLE 381 Key Information - Bio-Rad Laboratories, Inc.
• TABLE 382 Key Information - Guardant Health, Inc.
• TABLE 383 Key Information - Invitae Corporation
• TABLE 384 Key Information - Bio-Techne Corporation
• TABLE 385 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
• TABLE 386 Key Information - ICON PLC
• TABLE 387 Key Information - Natera Inc.
• TABLE 388 key information - Sysmex Corporation
• TABLE 389 Key Information - Laboratory Corporation of America holdings
• TABLE 390 Key Information - Invivoscribe, Inc.

List of Figures

• FIG 1 Methodology for the research
• FIG 2 Global Minimal Residual Disease Testing Market Share by Application, 2021
• FIG 3 Global Minimal Residual Disease Testing Market Share by Application, 2028
• FIG 4 Global Minimal Residual Disease Testing Market by Application, 2018 - 2028, USD Million
• FIG 5 Global Minimal Residual Disease Testing Market Share by End User, 2021
• FIG 6 Global Minimal Residual Disease Testing Market Share by End User, 2028
• FIG 7 Global Minimal Residual Disease Testing Market by End User, 2018 - 2028, USD Million
• FIG 8 Global Minimal Residual Disease Testing Market Share by Technology, 2021
• FIG 9 Global Minimal Residual Disease Testing Market Share by Technology, 2028
• FIG 10 Global Minimal Residual Disease Testing Market by Technology, 2018 - 2028, USD Million
• FIG 11 Global Minimal Residual Disease Testing Market Share by Region, 2021
• FIG 12 Global Minimal Residual Disease Testing Market Share by Region, 2028
• FIG 13 Global Minimal Residual Disease Testing Market by Region, 2018 - 2028, USD Million
• FIG 14 Recent strategies and developments: Guardant Health, Inc.
• FIG 15 Recent strategies and developments: Laboratory corporation of America Holding

The Global Minimal Residual Disease Testing Market size is expected to reach $2.7 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.

Minimal residual disease (MRD) testing is performed to identify solid tumors or hematological malignancies. MRD tests are mostly utilized for the diagnosis of a residual diagnosis in research and clinical settings. Through this test, the oncologists receive individualized information on the effectiveness of the utilized therapy from the ongoing monitoring of leftover cancer cells during the core therapy and throughout the remission stage.

Consequently, MRD tests also affect the decision-making for the selection of efficient treatment that would result in the improvement of the therapeutic results. Additionally, these tests can accurately forecast the likelihood of potential disease relapse. The onset of hematological malignancies or blood cancers takes place in the bone marrow, where stem cells give rise to red blood cells (RBC), white blood cells (WBC), and platelets.

These diseases affect the proper generation and operation of blood cells. These malignancies form when the development of healthy blood cells is obstructed by the unchecked proliferation of abnormal cells, which interferes with the normal functions of healthy cells. MRD is also known as measurable residual testing, and its test methods are used to determine the efficacy of cancer treatment and the need to direct future treatment strategies.

Leukemia, lymphoma, and myeloma are the three blood malignancies for which MRD testing is most commonly utilized, while its usage for other diseases' diagnoses is being researched. In addition, since the outcomes can be utilized to customize a patient's therapy, these tests are often considered helpful in the development of customized medicine.

COVID-19 Impact Analysis

The modifications to treatment occurred at a considerably slow pace owing to the pandemic's urgency. As a result, the setup of optimal time points to assess the disease response and evaluate for relapse by measuring the minimal residual disease for the newer methods could not be adequately established. This further made the intensification of therapy challenging by not providing an apt description of the therapy's duration and time points. Therefore, the COVID-19 pandemic had a negative effect on the minimal residual disease testing market.

Market Growth Factors

Increasing Cases Of Hematological Malignancies Across The World

Since the past few decades, the incidences of hematological malignancies have risen significantly. This increase includes the rising prevalence of hematological cancer subtypes as well. For example, leukemia was the eleventh leading mortality-causing factor that was associated with cancer in 2018. According to the Surveillance, Epidemiology, and End Results (SEER) Program, the disease also accounted for around 3.2% of all new emerging cancer cases in 2022.

Growing Use Of MRD Test Methods In The Diagnosis And Care Of Various Cancers

Since their development, minimal residual disease testing methods have become an essential part of the diagnosis of various blood cancers type. In acute lymphocytic leukemia (ALL), MRD tests are an integral part of routine testing. Several studies have also suggested that MRD tests are the most appropriate way to determine the appropriate treatment that would be extremely helpful for the first ALL therapy. These tests also help in the identification of patients that are at risk of relapse. Such factors aid in the expansion of the minimal residual disease testing market significantly.

Market Restraining Factors

Complex And Strict Regulations Regarding The Application Of MRD Tests

Like any other treatment and diagnostic methods, the minimal residual disease testing methodologies are also subject to specific issues related to the usage and suitability of these tests. The issue varies according to the tests. For example, multiparameter flow cytometry tests include complex data visualization, and these tests are unable to detect cytogenetic characteristics. Therefore, the strict regulations, along with the drawbacks of MRD tests, hampers the expansion and growth of the minimal residual disease testing market.

Technology Outlook

Based on technology, the minimal residual disease testing market is categorized into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and other technologies. The polymerase chain reaction (PCR) segment garnered the highest revenue share in the minimal residual disease testing market in 2021. The growth of the segment is because of the high practicality and simplicity of the PCR diagnostic devices in minimal residual disease testing. In addition, the PCR diagnostic device kits offer increased accessibility to information with a higher degree of sensitivity.

Application Outlook

On the basis of application, the minimal residual disease testing market is divided into hematological malignancies, leukemia, lymphoma, solid tumors, and other applications. The hematological malignancies segment acquired the largest revenue share in the minimal residual disease testing market in 2021. Cancers that start forming in blood-forming tissue like bone marrow are called hematological malignancies. Lymphoma, multiple myeloma, and leukemia are all types of hematological malignancies. MRD testing using PCR diagnosis enable the identification of cancer cells, including the rare kinds which are detectable in peripheral blood or bone marrow.

End User Outlook

Based on end user, the minimal residual disease testing market is segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutions, and others. The academic and research institutions segment garnered a remarkable growth rate in the minimal residual disease testing market in 2021. In academic and research institutions, the MRD test enables the conduction of more studies on rare cancer subjects. In addition, the results of MRD tests can be included as an endpoint in reports focusing on outcomes of clinical trials, which increases their use in clinical practices as well.

Regional Outlook

On the basis of region, the minimal residual disease testing market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the minimal residual disease testing market in 2021. MRD testing in North America is developing as a result of quick technological advancements, rising R&D expenditures, a developing patent pool along with an increase in applications.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.

Scope of the Study

Market Segments covered in the Report:

By Application

• Hematological Malignancies
• Leukemia
• Lymphoma
• Solid Tumors
• Others

By End User

• Hospitals & Specialty Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Others

By Technology

• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Flow Cytometry
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Bio-Rad Laboratories, Inc.
• Guardant Health, Inc.
• Invitae Corporation (ArcherDX, Inc.)
• Bio-Techne Corporation
• F. Hoffmann-La Roche Ltd.
• ICON plc (MolecularMD Corporation)
• Natera, Inc.
• Sysmex Corporation
• Laboratory Corporation of America Holdings
• Invivoscribe, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Minimal Residual Disease Testing Market, by Application
  • 1.4.2 Global Minimal Residual Disease Testing Market, by End User
  • 1.4.3 Global Minimal Residual Disease Testing Market, by Technology
  • 1.4.4 Global Minimal Residual Disease Testing Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market Overview

• 2.1 Introduction
  • 2.1.1 Overview
    • 2.1.1.1 Market Composition and Scenario
• 2.2 Key Factors Impacting the Market
  • 2.2.1 Market Drivers
  • 2.2.2 Market Restraints

Chapter 3. Global Minimal Residual Disease Testing Market by Application

• 3.1 Global Hematological Malignancies Market by Region
• 3.2 Global Leukemia Market by Region
• 3.3 Global Lymphoma Market by Region
• 3.4 Global Solid Tumors Market by Region
• 3.5 Global Others Market by Region

Chapter 4. Global Minimal Residual Disease Testing Market by End User

• 4.1 Global Hospitals & Specialty Clinics Market by Region
• 4.2 Global Diagnostic Laboratories Market by Region
• 4.3 Global Academic & Research Institutes Market by Region
• 4.4 Global Others Market by Region

Chapter 5. Global Minimal Residual Disease Testing Market by Technology

• 5.1 Global Polymerase Chain Reaction (PCR) Market by Region
• 5.2 Global Next-Generation Sequencing (NGS) Market by Region
• 5.3 Global Flow Cytometry Market by Region
• 5.4 Global Others Market by Region

Chapter 6. Global Minimal Residual Disease Testing Market by Region

• 6.1 North America Minimal Residual Disease Testing Market
  • 6.1.1 North America Minimal Residual Disease Testing Market by Application
    • 6.1.1.1 North America Hematological Malignancies Market by Country
    • 6.1.1.2 North America Leukemia Market by Country
    • 6.1.1.3 North America Lymphoma Market by Country
    • 6.1.1.4 North America Solid Tumors Market by Country
    • 6.1.1.5 North America Others Market by Country
  • 6.1.2 North America Minimal Residual Disease Testing Market by End User
    • 6.1.2.1 North America Hospitals & Specialty Clinics Market by Country
    • 6.1.2.2 North America Diagnostic Laboratories Market by Country
    • 6.1.2.3 North America Academic & Research Institutes Market by Country
    • 6.1.2.4 North America Others Market by Country
  • 6.1.3 North America Minimal Residual Disease Testing Market by Technology
    • 6.1.3.1 North America Polymerase Chain Reaction (PCR) Market by Country
    • 6.1.3.2 North America Next-Generation Sequencing (NGS) Market by Country
    • 6.1.3.3 North America Flow Cytometry Market by Country
    • 6.1.3.4 North America Others Market by Country
  • 6.1.4 North America Minimal Residual Disease Testing Market by Country
    • 6.1.4.1 US Minimal Residual Disease Testing Market
      • 6.1.4.1.1 US Minimal Residual Disease Testing Market by Application
      • 6.1.4.1.2 US Minimal Residual Disease Testing Market by End User
      • 6.1.4.1.3 US Minimal Residual Disease Testing Market by Technology
    • 6.1.4.2 Canada Minimal Residual Disease Testing Market
      • 6.1.4.2.1 Canada Minimal Residual Disease Testing Market by Application
      • 6.1.4.2.2 Canada Minimal Residual Disease Testing Market by End User
      • 6.1.4.2.3 Canada Minimal Residual Disease Testing Market by Technology
    • 6.1.4.3 Mexico Minimal Residual Disease Testing Market
      • 6.1.4.3.1 Mexico Minimal Residual Disease Testing Market by Application
      • 6.1.4.3.2 Mexico Minimal Residual Disease Testing Market by End User
      • 6.1.4.3.3 Mexico Minimal Residual Disease Testing Market by Technology
    • 6.1.4.4 Rest of North America Minimal Residual Disease Testing Market
      • 6.1.4.4.1 Rest of North America Minimal Residual Disease Testing Market by Application
      • 6.1.4.4.2 Rest of North America Minimal Residual Disease Testing Market by End User
      • 6.1.4.4.3 Rest of North America Minimal Residual Disease Testing Market by Technology
• 6.2 Europe Minimal Residual Disease Testing Market
  • 6.2.1 Europe Minimal Residual Disease Testing Market by Application
    • 6.2.1.1 Europe Hematological Malignancies Market by Country
    • 6.2.1.2 Europe Leukemia Market by Country
    • 6.2.1.3 Europe Lymphoma Market by Country
    • 6.2.1.4 Europe Solid Tumors Market by Country
    • 6.2.1.5 Europe Others Market by Country
  • 6.2.2 Europe Minimal Residual Disease Testing Market by End User
    • 6.2.2.1 Europe Hospitals & Specialty Clinics Market by Country
    • 6.2.2.2 Europe Diagnostic Laboratories Market by Country
    • 6.2.2.3 Europe Academic & Research Institutes Market by Country
    • 6.2.2.4 Europe Others Market by Country
  • 6.2.3 Europe Minimal Residual Disease Testing Market by Technology
    • 6.2.3.1 Europe Polymerase Chain Reaction (PCR) Market by Country
    • 6.2.3.2 Europe Next-Generation Sequencing (NGS) Market by Country
    • 6.2.3.3 Europe Flow Cytometry Market by Country
    • 6.2.3.4 Europe Others Market by Country
  • 6.2.4 Europe Minimal Residual Disease Testing Market by Country
    • 6.2.4.1 Germany Minimal Residual Disease Testing Market
      • 6.2.4.1.1 Germany Minimal Residual Disease Testing Market by Application
      • 6.2.4.1.2 Germany Minimal Residual Disease Testing Market by End User
      • 6.2.4.1.3 Germany Minimal Residual Disease Testing Market by Technology
    • 6.2.4.2 UK Minimal Residual Disease Testing Market
      • 6.2.4.2.1 UK Minimal Residual Disease Testing Market by Application
      • 6.2.4.2.2 UK Minimal Residual Disease Testing Market by End User
      • 6.2.4.2.3 UK Minimal Residual Disease Testing Market by Technology
    • 6.2.4.3 France Minimal Residual Disease Testing Market
      • 6.2.4.3.1 France Minimal Residual Disease Testing Market by Application
      • 6.2.4.3.2 France Minimal Residual Disease Testing Market by End User
      • 6.2.4.3.3 France Minimal Residual Disease Testing Market by Technology
    • 6.2.4.4 Russia Minimal Residual Disease Testing Market
      • 6.2.4.4.1 Russia Minimal Residual Disease Testing Market by Application
      • 6.2.4.4.2 Russia Minimal Residual Disease Testing Market by End User
      • 6.2.4.4.3 Russia Minimal Residual Disease Testing Market by Technology
    • 6.2.4.5 Spain Minimal Residual Disease Testing Market
      • 6.2.4.5.1 Spain Minimal Residual Disease Testing Market by Application
      • 6.2.4.5.2 Spain Minimal Residual Disease Testing Market by End User
      • 6.2.4.5.3 Spain Minimal Residual Disease Testing Market by Technology
    • 6.2.4.6 Italy Minimal Residual Disease Testing Market
      • 6.2.4.6.1 Italy Minimal Residual Disease Testing Market by Application
      • 6.2.4.6.2 Italy Minimal Residual Disease Testing Market by End User
      • 6.2.4.6.3 Italy Minimal Residual Disease Testing Market by Technology
    • 6.2.4.7 Rest of Europe Minimal Residual Disease Testing Market
      • 6.2.4.7.1 Rest of Europe Minimal Residual Disease Testing Market by Application
      • 6.2.4.7.2 Rest of Europe Minimal Residual Disease Testing Market by End User
      • 6.2.4.7.3 Rest of Europe Minimal Residual Disease Testing Market by Technology
• 6.3 Asia Pacific Minimal Residual Disease Testing Market
  • 6.3.1 Asia Pacific Minimal Residual Disease Testing Market by Application
    • 6.3.1.1 Asia Pacific Hematological Malignancies Market by Country
    • 6.3.1.2 Asia Pacific Leukemia Market by Country
    • 6.3.1.3 Asia Pacific Lymphoma Market by Country
    • 6.3.1.4 Asia Pacific Solid Tumors Market by Country
    • 6.3.1.5 Asia Pacific Others Market by Country
  • 6.3.2 Asia Pacific Minimal Residual Disease Testing Market by End User
    • 6.3.2.1 Asia Pacific Hospitals & Specialty Clinics Market by Country
    • 6.3.2.2 Asia Pacific Diagnostic Laboratories Market by Country
    • 6.3.2.3 Asia Pacific Academic & Research Institutes Market by Country
    • 6.3.2.4 Asia Pacific Others Market by Country
  • 6.3.3 Asia Pacific Minimal Residual Disease Testing Market by Technology
    • 6.3.3.1 Asia Pacific Polymerase Chain Reaction (PCR) Market by Country
    • 6.3.3.2 Asia Pacific Next-Generation Sequencing (NGS) Market by Country
    • 6.3.3.3 Asia Pacific Flow Cytometry Market by Country
    • 6.3.3.4 Asia Pacific Others Market by Country
  • 6.3.4 Asia Pacific Minimal Residual Disease Testing Market by Country
    • 6.3.4.1 China Minimal Residual Disease Testing Market
      • 6.3.4.1.1 China Minimal Residual Disease Testing Market by Application
      • 6.3.4.1.2 China Minimal Residual Disease Testing Market by End User
      • 6.3.4.1.3 China Minimal Residual Disease Testing Market by Technology
    • 6.3.4.2 Japan Minimal Residual Disease Testing Market
      • 6.3.4.2.1 Japan Minimal Residual Disease Testing Market by Application
      • 6.3.4.2.2 Japan Minimal Residual Disease Testing Market by End User
      • 6.3.4.2.3 Japan Minimal Residual Disease Testing Market by Technology
    • 6.3.4.3 India Minimal Residual Disease Testing Market
      • 6.3.4.3.1 India Minimal Residual Disease Testing Market by Application
      • 6.3.4.3.2 India Minimal Residual Disease Testing Market by End User
      • 6.3.4.3.3 India Minimal Residual Disease Testing Market by Technology
    • 6.3.4.4 South Korea Minimal Residual Disease Testing Market
      • 6.3.4.4.1 South Korea Minimal Residual Disease Testing Market by Application
      • 6.3.4.4.2 South Korea Minimal Residual Disease Testing Market by End User
      • 6.3.4.4.3 South Korea Minimal Residual Disease Testing Market by Technology
    • 6.3.4.5 Singapore Minimal Residual Disease Testing Market
      • 6.3.4.5.1 Singapore Minimal Residual Disease Testing Market by Application
      • 6.3.4.5.2 Singapore Minimal Residual Disease Testing Market by End User
      • 6.3.4.5.3 Singapore Minimal Residual Disease Testing Market by Technology
    • 6.3.4.6 Malaysia Minimal Residual Disease Testing Market
      • 6.3.4.6.1 Malaysia Minimal Residual Disease Testing Market by Application
      • 6.3.4.6.2 Malaysia Minimal Residual Disease Testing Market by End User
      • 6.3.4.6.3 Malaysia Minimal Residual Disease Testing Market by Technology
    • 6.3.4.7 Rest of Asia Pacific Minimal Residual Disease Testing Market
      • 6.3.4.7.1 Rest of Asia Pacific Minimal Residual Disease Testing Market by Application
      • 6.3.4.7.2 Rest of Asia Pacific Minimal Residual Disease Testing Market by End User
      • 6.3.4.7.3 Rest of Asia Pacific Minimal Residual Disease Testing Market by Technology
• 6.4 LAMEA Minimal Residual Disease Testing Market
  • 6.4.1 LAMEA Minimal Residual Disease Testing Market by Application
    • 6.4.1.1 LAMEA Hematological Malignancies Market by Country
    • 6.4.1.2 LAMEA Leukemia Market by Country
    • 6.4.1.3 LAMEA Lymphoma Market by Country
    • 6.4.1.4 LAMEA Solid Tumors Market by Country
    • 6.4.1.5 LAMEA Others Market by Country
  • 6.4.2 LAMEA Minimal Residual Disease Testing Market by End User
    • 6.4.2.1 LAMEA Hospitals & Specialty Clinics Market by Country
    • 6.4.2.2 LAMEA Diagnostic Laboratories Market by Country
    • 6.4.2.3 LAMEA Academic & Research Institutes Market by Country
    • 6.4.2.4 LAMEA Others Market by Country
  • 6.4.3 LAMEA Minimal Residual Disease Testing Market by Technology
    • 6.4.3.1 LAMEA Polymerase Chain Reaction (PCR) Market by Country
    • 6.4.3.2 LAMEA Next-Generation Sequencing (NGS) Market by Country
    • 6.4.3.3 LAMEA Flow Cytometry Market by Country
    • 6.4.3.4 LAMEA Others Market by Country
  • 6.4.4 LAMEA Minimal Residual Disease Testing Market by Country
    • 6.4.4.1 Brazil Minimal Residual Disease Testing Market
      • 6.4.4.1.1 Brazil Minimal Residual Disease Testing Market by Application
      • 6.4.4.1.2 Brazil Minimal Residual Disease Testing Market by End User
      • 6.4.4.1.3 Brazil Minimal Residual Disease Testing Market by Technology
    • 6.4.4.2 Argentina Minimal Residual Disease Testing Market
      • 6.4.4.2.1 Argentina Minimal Residual Disease Testing Market by Application
      • 6.4.4.2.2 Argentina Minimal Residual Disease Testing Market by End User
      • 6.4.4.2.3 Argentina Minimal Residual Disease Testing Market by Technology
    • 6.4.4.3 UAE Minimal Residual Disease Testing Market
      • 6.4.4.3.1 UAE Minimal Residual Disease Testing Market by Application
      • 6.4.4.3.2 UAE Minimal Residual Disease Testing Market by End User
      • 6.4.4.3.3 UAE Minimal Residual Disease Testing Market by Technology
    • 6.4.4.4 Saudi Arabia Minimal Residual Disease Testing Market
      • 6.4.4.4.1 Saudi Arabia Minimal Residual Disease Testing Market by Application
      • 6.4.4.4.2 Saudi Arabia Minimal Residual Disease Testing Market by End User
      • 6.4.4.4.3 Saudi Arabia Minimal Residual Disease Testing Market by Technology
    • 6.4.4.5 South Africa Minimal Residual Disease Testing Market
      • 6.4.4.5.1 South Africa Minimal Residual Disease Testing Market by Application
      • 6.4.4.5.2 South Africa Minimal Residual Disease Testing Market by End User
      • 6.4.4.5.3 South Africa Minimal Residual Disease Testing Market by Technology
    • 6.4.4.6 Nigeria Minimal Residual Disease Testing Market
      • 6.4.4.6.1 Nigeria Minimal Residual Disease Testing Market by Application
      • 6.4.4.6.2 Nigeria Minimal Residual Disease Testing Market by End User
      • 6.4.4.6.3 Nigeria Minimal Residual Disease Testing Market by Technology
    • 6.4.4.7 Rest of LAMEA Minimal Residual Disease Testing Market
      • 6.4.4.7.1 Rest of LAMEA Minimal Residual Disease Testing Market by Application
      • 6.4.4.7.2 Rest of LAMEA Minimal Residual Disease Testing Market by End User
      • 6.4.4.7.3 Rest of LAMEA Minimal Residual Disease Testing Market by Technology

Chapter 7. Company Profiles

• 7.1 Bio-Rad Laboratories, Inc.
  • 7.1.1 Company Overview
  • 7.1.2 Financial Analysis
  • 7.1.3 Segmental and Regional Analysis
  • 7.1.4 Research & Development Expenses
• 7.2 Guardant Health, Inc.
  • 7.2.1 Company Overview
  • 7.2.2 Financial Analysis
  • 7.2.3 Regional Analysis
  • 7.2.4 Research & Development Expenses
  • 7.2.5 Recent strategies and developments:
    • 7.2.5.1 Partnerships, Collaborations, and Agreements:
    • 7.2.5.2 Product Launches and Product Expansions:
• 7.3 Invitae Corporation (ArcherDX, Inc.)
  • 7.3.1 Company Overview
  • 7.3.2 Financial Analysis
  • 7.3.3 Regional Analysis
  • 7.3.4 Research & Development Expenses
  • 7.3.5 Recent strategies and developments:
    • 7.3.5.1 Partnerships, Collaborations, and Agreements:
• 7.4 Bio-Techne Corporation
  • 7.4.1 Company Overview
  • 7.4.2 Financial Analysis
  • 7.4.3 Segmental and Regional Analysis
  • 7.4.4 Research & Development Expenses
• 7.5 F. Hoffmann-La Roche Ltd.
  • 7.5.1 Company Overview
  • 7.5.2 Financial Analysis
  • 7.5.3 Segmental and Regional Analysis
  • 7.5.4 Research & Development Expense
  • 7.5.5 Recent strategies and developments:
    • 7.5.5.1 Approvals & Trails:
• 7.6 ICON plc (MolecularMD Corporation)
  • 7.6.1 Company Overview
  • 7.6.2 Financial Analysis
  • 7.6.3 Regional Analysis
  • 7.6.4 Recent strategies and developments:
    • 7.6.4.1 Partnerships, Collaborations, and Agreements:
• 7.7 Natera Inc.
  • 7.7.1 Company Overview
  • 7.7.2 Financial Analysis
  • 7.7.3 Regional Analysis
  • 7.7.4 Research & Development Expenses
• 7.8 Sysmex Corporation
  • 7.8.1 Company Overview
  • 7.8.2 Financial Analysis
  • 7.8.3 Regional Analysis
  • 7.8.4 Research & Development Expense
• 7.9 Laboratory Corporation of America Holdings
  • 7.9.1 Company Overview
  • 7.9.2 Financial Analysis
  • 7.9.3 Segmental Analysis
  • 7.9.4 Recent strategies and developments:
    • 7.9.4.1 Partnerships, Collaborations, and Agreements:
    • 7.9.4.2 Product Launches and Product Expansions:
• 7.10. Invivoscribe, Inc.
  • 7.10.1 Company Overview
  • 7.10.2 Recent strategies and developments:
    • 7.10.2.1 Partnerships, Collaborations, and Agreements: